02279nas a2200253   4500000000100000008004100001260004400042653003300086653002600119653001800145653001900163653001600182100001100198700001500209700001400224700001300238700001200251245015800263856006500421300000600486490000700492520151200499022001402011       2025                            d  bSpringer Science and Business Media LLC10aCutaneous Leishmaniasis (CL)10aMeglumine Antimoniate10aRenal failure10aRenal Dialysis10aDermatology1 aArab H1 aAlsaffaf Y1 aAldolly A1 aDukhan A1 aDouri T00aSuccessful treatment of meglumine antimoniate in patient with cutaneous leishmaniasis with end-stage renal failure undergoing hemodialysis: a case report  uhttps://link.springer.com/article/10.1186/s13256-025-05331-x  a60 v193 a<p><strong>Background</strong> Cutaneous leishmaniasis is the most common form of leishmaniasis. Meglumine antimoniate is the frst line of available treatment in developing countries. There is limited research on the renal efects of antimonial compounds.</p>

<p><strong>Case presentation</strong> A 25-year-old Arab male patient presented to the dermatology clinic with a 9-month history of multiple skin lesions. The patient had a history of end-stage renal failure. Physical examination of these lesions revealed ulcerated nodules that are painless and non-itchy located on the hands, forearms, feet, and neck. The lesions were diagnosed as cutaneous leishmaniasis tropica on the basis of the histopathology of a skin biopsy and the patient’s region, which is endemic to female sandfies and this specifc subtype cutaneous leishmaniasis. The patient started taking meglumine antimoniate intramuscular administration after the dialysis session at a dose of 750 mg/kg per week. The lesions showed partial to complete remission after 60 days of treatment without any meglumine antimoniate side efects. The patient has not experienced any relapse of leishmaniasis since kidney transplantation 6 years ago.</p>

<p><strong>Conclusion</strong> This case highlights knowledge gaps in the therapeutic approach for using meglumine antimoniate in patients with end-stage renal failure undergoing hemodialysis. The need for further research and clinical trials to establish clear guidelines is essential.</p>
  a1752-1947